2/27
01:46 pm
inmb
INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript [Seeking Alpha]
Low
Report
INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript [Seeking Alpha]
2/27
12:11 am
inmb
INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript [Seeking Alpha]
Medium
Report
INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript [Seeking Alpha]
2/23
09:43 am
inmb
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar [Yahoo! Finance]
Low
Report
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar [Yahoo! Finance]
2/23
09:25 am
inmb
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
Low
Report
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
2/19
12:15 pm
inmb
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
Low
Report
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
2/12
04:11 pm
inmb
INmune Bio submits pre-submission package for CORDStrom with MHRA [Yahoo! Finance]
Low
Report
INmune Bio submits pre-submission package for CORDStrom with MHRA [Yahoo! Finance]
2/12
07:00 am
inmb
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
High
Report
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
2/10
08:00 am
inmb
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
Medium
Report
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
1/27
09:25 am
inmb
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
Medium
Report
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
12/14
01:26 am
inmb
Medium
Report
12/5
07:00 am
inmb
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
Low
Report
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform